The sustained release of the acetylcholinesterase inhibitor ZT-1 confers the potential for a more efficient neuroprotection in rats | Debio 9902 - ZT-1 | /

Home|Careers|Contact us

News

20.11.2008
Debiopharm and Aurigene sign licensing agreement for the development and commercialisation of Debio 0617, a novel inhibitor of an undisclosed oncology pathway
17.11.2008
Debiopharm and Pharmaleads sign license agreement for Debio 0827 or PL37 in treatment of chronic pain conditions

The sustained release of the acetylcholinesterase inhibitor ZT-1 confers the potential for a more efficient neuroprotection in rats

P. Scalfaro, V. Nicolas, M.P. Simonin, S. Charbon, M. McCormick, F. Heimgartner
(presented at the Neurobiology of Aging Conference in New Orleans, Nov 2003)
document_in_PDF